Screener
Supernus Pharmaceuticals SUPN PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 78,094 | 65,325 |
| Total current assets | 731,580 | 644,182 |
| Restricted cash | 1,450 | 1,450 |
| Property and equipment, net | 10,042 | 10,531 |
| Intangible assets, net | 549,712 | 569,456 |
| Goodwill | 120,668 | 124,882 |
| Deferred income tax assets, net | 30,820 | 38,351 |
| Other assets | 56,453 | 63,796 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's PP&E (net)?
- Supernus Pharmaceuticals (SUPN) reported PP&E (net) of $10.04M in Q1 2026.
- How has Supernus Pharmaceuticals's PP&E (net) changed year-over-year?
- Supernus Pharmaceuticals's PP&E (net) decreased by 11.4% year-over-year, from $11.34M to $10.04M.
- What is the long-term trend for Supernus Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's PP&E (net) has grown at a -22.6% compound annual growth rate (CAGR), from $37.82M to $10.53M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Supernus Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude